Inflammatory Bowel Disease, Volatile Organic Compounds
Conditions
Brief summary
The availability of noninvasive biomarkers for diagnosis and stratification of inflammatory bowel disease (IBD) courses is lacking. Thus, the aim of this study is to evaluated the accuracy of exhaled breath volatile metabolite analysis on diagnosis and stratification of patients with inflammatory bowel disease.
Detailed description
Background: The diagnosis and differentiation of inflammatory bowel diseases (IBD) is challenging due to the absence of a gold standard diagnostic modality for confirmation. Exhaled breath volatile metabolite analysis focusing on diagnosis and differentiation of IBD is a promising approach. Thus, the aim of this study is to evaluated the accuracy of exhaled breath volatile metabolite analysis for patients with inflammatory bowel disease. Method: A single center, prospective study of diagnostic testing will be conducted, recruiting crohn's disease (CD), ulcerative colitis (UC), and healthy controls (HC). The exhaled breath volatile metabolite will be analyzed using gas chromatography/mass spectrometry (GC-MS). The informations of patient's disease location, disease activity, laboratory parameters and current medications will be collected to determine the feasibility of exhaled breath volatile metabolite analysis.
Interventions
PROCEDUREBreath sampling for volatile organic compounds
Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
Sponsors
Keimyung University Dongsan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) * Healthy controls who do not have any gastrointestinal disease or symptom
Exclusion criteria
* Pregnant or lactating woman * Subjects who diagnosed liver cirrhosis, severe congestive heart failure, severe renal insufficiency, uncontrolled hypertension, endocrine disorder, metabolic disorder, prior malignancy, immune deficiency * Subjects with mental retardation and cognitive impairment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volatile organic compounds differentiating the study groups | At the time of breath sampling | Volatile organic compounds analysed by GC-MS between the study groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Volatile organic compounds differentiating the disease activity | At the time of breath sampling | Volatile organic compounds analysed by GC-MS between the study groups |
Countries
South Korea
Contacts
Primary ContactYoo Jin Lee, Professor
Outcome results
None listed